What’s the current market cap for Grifols Class A stock?

Grifols Class A (GRF) has a market cap of €5.5bn as of June 14, 2026.

What is the P/E ratio for Grifols Class A stock?

The price to earnings (P/E) ratio for Grifols Class A (GRF) stock is 14.92 as of June 14, 2026.

Does Grifols Class A stock pay dividends?

Yes, the Grifols Class A (GRF) stock pays dividends to shareholders. As of June 14, 2026, the dividend rate is €0.1215 and the yield is 1.34%. Grifols Class A has a payout ratio of 30.84% on a trailing twelve-month basis.

When is the next Grifols Class A dividend payment date?

The next Grifols Class A (GRF) dividend payment date is unconfirmed.

What is the beta indicator for Grifols Class A?

Grifols Class A (GRF) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Grifols Class A stock | €GRF Share Price

05:30

09:10

12:45

16:25

20:00

About Grifols Class A

Grifols SA, operating under the ticker GRF, is a biopharmaceutical company specialized in the production of plasma-derived medicines. Founded in 1940 and headquartered in Barcelona, Spain, Grifols is engaged in the diagnosis, prevention, and treatment of a variety of diseases, with a strong focus on immunology, hematology, and intensive care sectors. The company operates globally, leveraging advanced technologies and rigorous quality processes to provide essential medical products.

Ticker

€GRF

Sector

Health

Primary listing

BME

Employees

25,000

Headquarters

Barcelona, Spain

Website

www.grifols.com

Grifols Class A Metrics

BasicAdvanced

€5.5bn

14.92

€0.61

1.17

€0.12

1.34%

What the Analysts think about Grifols Class A

Analyst ratings (Buy, Hold, Sell) for Grifols Class A stock.

Bulls say / Bears say

FY2025 net profit more than doubled to €402 million, with revenue up 7% to €7.5 billion and adjusted EBITDA rising to €1.825 billion in line with expectations, highlighting robust growth across its plasma therapies portfolio (MarketScreener).

For 2026 Grifols guides to adjusted EBITDA growth of over 25% to between €1.95–€1.98 billion and free cash flow of at least €500 million, underscoring a strategic pivot toward profitability and deleveraging (MarketScreener).

Grifols formalised refinancing of its 2027 debt maturities via a €4.7 billion credit facility structured in three tranches, bolstering liquidity and extending its debt profile beyond 2028 (Cinco Días).

Grifols estimates a €70 million FX headwind to FY2025 adjusted EBITDA and faced a €144 million revenue and €23 million EBITDA drag in Q1 2026 due to adverse currency movements, eroding profit margins (Reuters via TradingView).

FY2025 net profit of €402 million missed the €427 million consensus forecast, raising concerns over earnings volatility and forecast reliability (MarketScreener).

Health Canada imposed license conditions on Grifols’ Canadian blood collection operations after two donor deaths and systemic deficiencies were identified, highlighting regulatory and operational risks in critical markets (Bloomberg).

Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2026.

Grifols Class A Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Grifols Class A Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Buy €GRF

€

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

FY2025 net profit of €402 million missed the €427 million consensus forecast, raising concerns over earnings volatility and forecast reliability (MarketScreener).

Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2026.

About Grifols Class A

Ticker

Primary listing

Employees

Grifols Class A Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Grifols Class A

Analyst Ratings

Bulls say / Bears say

Grifols Class A Financial Performance

Income Statement

Grifols Class A Earnings Performance

Earnings per share (EPS)

Buy €GRF

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Grifols Class A/€GRF

About Grifols Class A

Ticker

Primary listing

Employees

Grifols Class A Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Grifols Class A

Analyst Ratings

Bulls say / Bears say

Grifols Class A Financial Performance

Income Statement

Grifols Class A Earnings Performance

Earnings per share (EPS)

Buy €GRF

Upcoming events

No upcoming events

What’s the current market cap for Grifols Class A stock?

What is the P/E ratio for Grifols Class A stock?

Does Grifols Class A stock pay dividends?

When is the next Grifols Class A dividend payment date?

What is the beta indicator for Grifols Class A?

Bulls say / Bears say